Dosimetric consequences of increased seed strength for I-125 prostate implants

Based on the findings of an earlier planning study, we compared post-implant dose distributions for two groups of 20 consecutive patients treated to 145 Gy with 0.414 and 0.526 U I-125 seeds. Dosimetric coverage as measured by the key clinical index D90 was significantly better for the higher-strength seeds, with no apparent deleterious effects.